Ventria Bioscience

OverviewSuggest Edit

Ventria Bioscience develops life-saving medicines targeting inflammatory, infectious and gastrointestinal diseases. It produces medicinal products that are enabled by ExpressTec, a breakthrough in biomanufacturing that is meant to enable global access and affordability. The Company also sells animal-component-free cell culture reagents and designs animal-component-free cell culture media formulations for cell-based vaccines, cellular therapies and biomanufacturing.

HQJunction City, KS, US
Employee Ratings4.2

Latest Updates

Employees (est.) (Jan 2022)32
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ventria Bioscience

Scott Deeter

Scott Deeter

President & Chief Executive Officer, Director
Vladimir Akoyev

Vladimir Akoyev

Vice President Analytical Development
William H. Rutter

William H. Rutter

William W. Crouse

William W. Crouse

Ron Backman

Ron Backman

Vice President, Quality
Randall Alfano

Randall Alfano

Vice President, Product Development
Show more

Ventria Bioscience Office Locations

Ventria Bioscience has offices in Junction City and Aurora
Junction City, KS, US (HQ)
2718 Industrial St
Aurora, CO, US
12635 E Montview Blvd
Show all (2)

Ventria Bioscience Financials and Metrics

Summary Metrics

Founding Date


Ventria Bioscience total Funding

$7.7 m

Ventria Bioscience investors

Ventria Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Ventria Bioscience Online and Social Media Presence

Embed Graph

Ventria Bioscience News and Updates

Insights on the Lactoferrin Global Market to 2027 - Featuring Glanbia, Ventria Bioscience and MP Biomedicals Among Others

DUBLIN, Jan. 18, 2022 /PRNewswire/ -- The "Global Lactoferrin Market By Function, By Application, By Regional Outlook, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027" report has been added to's offering. The Global Lactoferrin Market size is expected to...

Ventria Bioscience Blogs

CuraVive, the Next Generation Plant-Based Food Ingredients

New Business Unit Announcement Ventria Bioscience announces the launch of its new business unit, CuraVive. The new subsidiary is solely focused on leading the innovation in plant-based functional food ingredients. CuraVive applies over 20 years of Ventria Bioscience’s plant protein production experi…

Ventria Bioscience Inc. Scores Key Victory in Fight Against Infringing Chinese Recombinant Albumin

For immediate release – Junction City, KS  Last week, Ventria Bioscience Inc. obtained an important win in its effort to stop the importation and sale of infringing recombinant albumin made in China by Wuhan Healthgen Biotechnology Corp. On August 18, 2021, the U.S. International Trade Commission (I…

Secretory IgA: potential new weapon against respiratory transmission of SARS-CoV-2?

  The ongoing COVID-19 pandemic has become a major source of disruption and upheaval to normal daily routines. The repeated opening and re-shuttering of schools and universities in response to spiking case numbers, for example, highlights the need for preventative treatments before a return to norma…

Could IgA from Human Breast Milk Offer Insights into Potential Treatments for COVID-19?

As of the date of this writing, there have been more than 8 million confirmed cases of COVID-19 worldwide, and close to half a million deaths. The pandemic’s initial, exponential growth trajectory has been contained through massive voluntary and mandatory isolation efforts; however, these have had t…

Ventria Bioscience’s ExpressTec Delivers the Power to Improve the Health Status of Children in Developing Countries

Junction City, Kansas – November 21, 2019 – A recent publication, Human Milk Proteins: Their Power to Improve the Health Status of Children in Developing Countries, explores the critical health benefits of synthetic human breastmilk proteins for children in developing countries. In poverty-stricken …

Human Milk Proteins: Their Power to Improve the Health Status of Children in Developing Countries

It has long been known that human breastmilk provides crucial health advantages to newborn infants as they develop, and has been a topic of intense research. Current clinical innovations seek to harness the benefits of human breastmilk to address global medical needs. With functions such as energy p…

Ventria Bioscience Frequently Asked Questions

  • When was Ventria Bioscience founded?

    Ventria Bioscience was founded in 1993.

  • Who are Ventria Bioscience key executives?

    Ventria Bioscience's key executives are Scott Deeter, Vladimir Akoyev and William H. Rutter.

  • How many employees does Ventria Bioscience have?

    Ventria Bioscience has 32 employees.

  • Who are Ventria Bioscience competitors?

    Competitors of Ventria Bioscience include Alkahest, Kamada Pharmaceuticals and JCR Pharmaceuticals.

  • Where is Ventria Bioscience headquarters?

    Ventria Bioscience headquarters is located at 2718 Industrial St, Junction City.

  • Where are Ventria Bioscience offices?

    Ventria Bioscience has offices in Junction City and Aurora.

  • How many offices does Ventria Bioscience have?

    Ventria Bioscience has 2 offices.